Onconova Therapeutics, Inc. – NASDAQ:ONTX

Financial Health
0
1
2
3
4
5
6
7
8
9

Onconova Therapeutics stock price monthly change

+45.89%
month

Onconova Therapeutics stock price quarterly change

+25.95%
quarter

Onconova Therapeutics stock price yearly change

+36.17%
year

Onconova Therapeutics key metrics

Market Cap
20.90M
Enterprise value
N/A
P/E
-0.76
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
41.51
Price/Book
0.49
PEG ratio
-0.14
EPS
-0.87
Revenue
226K
EBITDA
-19.36M
Income
-18.15M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-7997.05%
Oper. margin
-8223.89%
Gross margin
0%
EBIT margin
-8223.89%
EBITDA margin
-8566.37%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Onconova Therapeutics stock price history

Onconova Therapeutics stock forecast

Onconova Therapeutics financial statements

Onconova Therapeutics, Inc. (NASDAQ:ONTX): Profit margin
Jun 2023 57K -4.25M -7456.14%
Sep 2023 57K -4.73M -8314.04%
Dec 2023 56K -4.18M -7471.43%
Mar 2024 56K -4.98M -8898.21%
Onconova Therapeutics, Inc. (NASDAQ:ONTX): Analyst Estimates
2025 300K -28.4M -9466.67%
2026 300K -33M -11000%
2027 300K -19.93M -6646.47%
2028 400K -24.34M -6086.77%
  • Analysts Price target

  • Financials & Ratios estimates

Onconova Therapeutics, Inc. (NASDAQ:ONTX): Earnings per share (EPS)
2023-05-15 -0.3 -0.2
Onconova Therapeutics, Inc. (NASDAQ:ONTX): Debt to assets
Jun 2023 30468000 11.57M 37.97%
Sep 2023 27038000 12.52M 46.31%
Dec 2023 22683000 12.01M 52.95%
Mar 2024 18172000 12.15M 66.9%
Onconova Therapeutics, Inc. (NASDAQ:ONTX): Cash Flow
Jun 2023 -4.49M 0 0
Sep 2023 -4.46M -14K 0
Dec 2023 -4.43M -13.99B 0
Mar 2024 -4.42M 0 0

Onconova Therapeutics alternative data

Onconova Therapeutics, Inc. (NASDAQ:ONTX): Employee count
Aug 2023 16
Sep 2023 16
Oct 2023 16
Nov 2023 16
Dec 2023 16
Jan 2024 16
Feb 2024 16
Mar 2024 16
Apr 2024 16
May 2024 16
Jun 2024 16
Jul 2024 16

Onconova Therapeutics other data

2.17% -5.25%
of ONTX is owned by hedge funds
453.27K -1.09M
shares is hold by hedge funds

Onconova Therapeutics, Inc. (NASDAQ:ONTX): Insider trades (number of shares)
Period Buy Sel
Feb 2021 85000 0
Sep 2021 13095 0
Nov 2021 1000 0
Jan 2022 6000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
GUERIN MARK PATRICK officer: CFO AND COO
Common Stock 6,900 N/A N/A
Option
GUERIN MARK PATRICK officer: CFO AND COO
Restricted Stock Units 6,900 N/A N/A
Option
FRUCHTMAN STEVEN M director, officer.. Common Stock 21,320 N/A N/A
Option
FRUCHTMAN STEVEN M director, officer.. Restricted Stock Units 21,320 N/A N/A
Option
GUERIN MARK PATRICK officer: CFO AND COO
Common Stock 4,750 N/A N/A
Option
GUERIN MARK PATRICK officer: CFO AND COO
Restricted Stock Units 4,750 N/A N/A
Option
FRUCHTMAN STEVEN M director, officer.. Common Stock 12,567 N/A N/A
Option
FRUCHTMAN STEVEN M director, officer.. Restricted Stock Units 12,567 N/A N/A
Option
GUERIN MARK PATRICK officer: CFO AND COO
Common Stock 5,500 N/A N/A
Option
GUERIN MARK PATRICK officer: CFO AND COO
Restricted Stock Units 5,500 N/A N/A
Insider Compensation
Dr. Steven M. Fruchtman (1951) Chief Executive Officer, Pres & Director $865,440
Mr. Mark Patrick Guerin CPA (1969) Chief Financial Officer
$512,190
Tuesday, 2 April 2024
globenewswire.com
Friday, 8 March 2024
globenewswire.com
Friday, 8 December 2023
globenewswire.com
Tuesday, 28 November 2023
GlobeNewsWire
Tuesday, 14 November 2023
Seeking Alpha
Tuesday, 7 November 2023
GlobeNewsWire
Thursday, 28 September 2023
GlobeNewsWire
Thursday, 10 August 2023
Seeking Alpha
Monday, 15 May 2023
Seeking Alpha
Zacks Investment Research
Thursday, 4 May 2023
GlobeNewsWire
Tuesday, 25 April 2023
PennyStocks
Monday, 24 April 2023
PennyStocks
Friday, 21 April 2023
PennyStocks
Thursday, 16 March 2023
Seeking Alpha
Thursday, 9 March 2023
GlobeNewsWire
Wednesday, 7 December 2022
GlobeNewsWire
Monday, 28 November 2022
GlobeNewsWire
Monday, 14 November 2022
Seeking Alpha
Zacks Investment Research
Monday, 7 November 2022
GlobeNewsWire
Thursday, 22 September 2022
GlobeNewsWire
Thursday, 1 September 2022
GlobeNewsWire
Thursday, 11 August 2022
Seeking Alpha
Zacks Investment Research
Wednesday, 11 May 2022
Seeking Alpha
Wednesday, 23 March 2022
GlobeNewsWire
Thursday, 17 March 2022
Seeking Alpha
Thursday, 10 March 2022
GlobeNewsWire
Tuesday, 4 January 2022
GlobeNewsWire
  • When is Onconova Therapeutics's next earnings date?

    Unfortunately, Onconova Therapeutics's (ONTX) next earnings date is currently unknown.

  • Does Onconova Therapeutics pay dividends?

    No, Onconova Therapeutics does not pay dividends.

  • How much money does Onconova Therapeutics make?

    Onconova Therapeutics has a market capitalization of 20.90M. Onconova Therapeutics made a loss 18.95M US dollars in net income (profit) last year or -$0.2 on an earnings per share basis.

  • What is Onconova Therapeutics's stock symbol?

    Onconova Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ONTX".

  • What is Onconova Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Onconova Therapeutics?

    Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Onconova Therapeutics's key executives?

    Onconova Therapeutics's management team includes the following people:

    • Dr. Steven M. Fruchtman Chief Executive Officer, Pres & Director(age: 74, pay: $865,440)
    • Mr. Mark Patrick Guerin CPA Chief Financial Officer(age: 56, pay: $512,190)
  • How many employees does Onconova Therapeutics have?

    As Jul 2024, Onconova Therapeutics employs 16 workers.

  • When Onconova Therapeutics went public?

    Onconova Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 25 Jul 2013.

  • What is Onconova Therapeutics's official website?

    The official website for Onconova Therapeutics is onconova.com.

  • Where are Onconova Therapeutics's headquarters?

    Onconova Therapeutics is headquartered at 12 Penns Trail, Newtown, PA.

  • How can i contact Onconova Therapeutics?

    Onconova Therapeutics's mailing address is 12 Penns Trail, Newtown, PA and company can be reached via phone at +267 7593680.

Onconova Therapeutics company profile:

Onconova Therapeutics, Inc.

onconova.com
Exchange:

NASDAQ

Full time employees:

16

Industry:

Biotechnology

Sector:

Healthcare

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

12 Penns Trail
Newtown, PA 18940

CIK: 0001130598
ISIN: US68232V8019
CUSIP: 68232V801